The hypnotic and sedative medicine sales in Sweden have shown significant growth from 2013 to 2020, increasing from 314.9 to 816.9 million SEK. However, this growth faced a sharp decline in 2021, dropping to 604.2 million SEK, followed by gradual recovery in subsequent years, reaching 676 million SEK in 2023.
The year-on-year variation over the last two years was marked by a significant drop of 26.04% in 2021, a rebound of 9.75% in 2022, and a modest increase of 1.95% in 2023. The 5-year CAGR up to 2023 stood at 2.15%, reflecting moderate growth following the substantial dip in 2021.
Looking ahead, forecasted figures indicate steady growth in the hypnotic and sedative medicine market, with values expected to reach 749.3 million SEK by 2028. The projected 5-year CAGR from 2023 to 2028 is 1.63%, signifying a stable increase with an overall forecasted growth rate of 8.44%.
Given these trends, future areas to monitor include the impact of healthcare policy changes, advances in alternative therapies, and potential market saturation. Trends in mental health awareness and an aging population may also drive future demand. Monitoring these factors closely will be crucial for anticipating market shifts and planning strategically.
